Patent Expiry
ABBV: BYVALSON: recorded patent 7838552 expiry
October 4, 2027 · NEBIVOLOL HYDROCHLORIDE; VALSARTAN. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 4, 2027
- Company
- AbbVie Inc. (ABBV)
- Drug
- NEBIVOLOL HYDROCHLORIDE; VALSARTAN
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Patent Expiry
BYVALSON: recorded patent 7838552 expiry
Orange Book application NDA206302, product 001, listed patent 7838552 expiry. Overall loss of exclusivity and current company rights: unknown.FDA source
- Company
- AbbVie Inc. (ABBV)
- Drug
- NEBIVOLOL HYDROCHLORIDE; VALSARTAN
Other upcoming events for ABBV
Earnings ReportEarnings: AbbVie to Host Third-Quarter 2026 Earnings Conference Call
Phase 1 StartPhase1_Start: A Phase 1, Double-blind, Placebo-Controlled, First-in-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses ofABBV-1162 in Healthy Subjects
Phase 3 StartPhase3_Start: A Phase 3 Multicenter, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) Compared to Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (Dara-CyBorD) in Subjects With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Phase 3 StartPhase3_Start: A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)
Phase 3 StartPhase3_Start: A Phase 3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Expressing c-Met Protein Level Above a Defined Cutoff